In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 11, 2012, Pages 2673-2681

  Yu, Qianru ^a   Griffin, Edward F ^a   Moreau Marquis, Sophie ^a   Schwartzman, Joseph D ^b   Stanton, Bruce A ^a   O'Toole, George A ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

AZLI; Co culture; Monotherapy; Tolerance

Indexed keywords

AZTREONAM LYSINE; EXOPOLYSACCHARIDE; TOBRAMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; BIOFILM; COCULTURE; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFECT; EPITHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PSEUDOMONAS AERUGINOSA; RESPIRATORY EPITHELIUM;

ANTI-BACTERIAL AGENTS; AZTREONAM; BIOFILMS; CYSTIC FIBROSIS; EPITHELIAL CELLS; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TIME FACTORS; TOBRAMYCIN;

EID: 84867615387     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks296     Document Type: Article

References (45)

1. Riordan JR, Rommens JM, Kerem B et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245: 1066-73.
2. Kerem B, Rommens JM, Buchanan JA et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245: 1073-80.
3. Cystic Fibrosis Foundation. Patient Registry Annual Data Report 2010. http://www.cff.org/UploadedFiles/LivingWithCF/CareCenterNetwork/PatientRegistry/2010-Patient-Registry-Report.pdf (2 July 2012, date last accessed).
4. Heijerman H. Infection and inflammation in cystic fibrosis: a short review. J Cyst Fibros 2005; 4 Suppl 2: 3-5.
5. Moreau-Marquis S, O'Toole GA, Stanton BA. Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells. Am J Respir Cell Mol Biol 2009; 41: 305-13.
6. Geller DE. Aerosol antibiotics in cystic fibrosis. Respir Care 2009; 54: 658-70.
7. Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996; 60: 539-74.
8. Singh PK, Schaefer AL, Parsek MR et al. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000; 407: 762-4.
9. Mah TF, O'Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 2001; 9: 34-9.
10. Hoiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med 2011; 9: 32.
11. Elborn JS, Henig NR. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine. Expert Opin Pharmacother 2010; 11: 1373-85.
12. Sykes RB, Bonner DP, Bush K et al. Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic Gramnegative bacteria. Antimicrob Agents Chemother 1982; 21: 85-92.
13. McCoy KS, Quittner AL, Oermann CM et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008; 178: 921-8.
14. Retsch-Bogart GZ, Quittner AL, Gibson RL et al. Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest 2009; 135: 1223-32.
15. Oermann CM, Retsch-Bogart GZ, Quittner AL et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010; 45: 1121-34.
16. Parkins MD, Elborn JS. Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis. Exp Rev Respir Med 2010; 4: 435-44.
17. Anderson GG, Moreau-Marquis S, Stanton BA et al. In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells. Infect Immun 2008; 76: 1423-33.
18. Moreau-Marquis S, Stanton BA, O'Toole GA. Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway. Pulm Pharmacol Ther 2008; 21: 595-9.
19. Bloemberg G, O'Toole GA, Lugtenberg B et al. Green fluorescent protein as a marker for Pseudomonas spp. Appl Environ Microbiol 1997; 63: 4543-51.
20. Friedman L, Kolter R. Two genetic loci produce distinct carbohydraterich structural components of the Pseudomonas aeruginosa biofilm matrix. J Bacteriol 2004; 186: 4457-65.
21. Garrett ES, Perlegas D, Wozniak DJ. Negative control of flagellum synthesis in Pseudomonas aeruginosa is modulated by the alternative sigma factor AlgT (AlgU). J Bacteriol 1999; 181: 7401-4.
22. Ma L, Jackson KD, Landry RM et al. Analysis of Pseudomonas aeruginosa conditional Psl variants reveals roles for the Psl polysaccharide in adhesion and maintaining biofilm structure postattachment. J Bacteriol 2006; 188: 8213-21.
23. Zegans ME, Wozniak D, Griffin E et al. Pseudomonas aeruginosa exopolysaccharide Psl promotes resistance to the biofilm inhibitor polysorbate 80. Antimicrob Agents Chemother 2012; doi:10.1128/ AAC.00373-12.
24. Wahba AH, Darrell JH. The identification of atypical strains of Pseudomonas aeruginosa. J Gen Microbiol 1965; 38: 329-42.
25. Geller DE, Pitlick WH, Nardella PA et al. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002; 122: 219-26.
26. Bruscia E, Sangiuolo F, Sinibaldi P et al. Isolation of CF cell lines corrected at DF508-CFTR locus by SFHR-mediated targeting. Gene Ther 2002; 9: 683-5.
27. Cozens AL, Yezzi MJ, Kunzelmann K et al. CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells. Am J Respir Cell Mol Biol 1994; 10: 38-47.
28. Hentchel-Franks K, Lozano D, Eubanks-Tarn V et al. Activation of airway Cl2 secretion in human subjects by adenosine. Am J Respir Cell Mol Biol 2004; 31: 140-6.
29. Moreau-Marquis S, Bomberger JM, Anderson GG et al. The DF508-CFTR mutation results in increased biofilm formation by Pseudomonas aeruginosa by increasing iron availability. Am J Physiol Lung Cell Mol Physiol 2008; 295: L25-37.
30. Mah TF, Pitts B, Pellock B et al. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 2003; 426: 306-10.
31. Kirisits MJ, Parsek MR. Does Pseudomonas aeruginosa use intercellular signalling to build biofilm communities? Cell Microbiol 2006; 8: 1841-9.
32. Orlicek SL. Aztreonam. Semin Pediatr Infect Dis 1999; 10: 45-50.
33. Ghani M, Soothill JS. Ceftazidime, gentamicin, and rifampicin, in combination, kill biofilms of mucoid Pseudomonas aeruginosa. Can J Microbiol 1997; 43: 999-1004.
34. Dales L, Ferris W, Vandemheen K et al. Combination antibiotic susceptibility of biofilm-grown Burkholderia cepacia and Pseudomonas aeruginosa isolated from patients with pulmonary exacerbations of cystic fibrosis. Eur J Clin Microbiol Infect Dis 2009; 28: 1275-9.
35. Herrmann G, Yang L, Wu H et al. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. J Infect Dis 2010; 202: 1585-92.
36. Araoka H, Baba M, Tateda K et al. In vitro combination effects of aztreonam and aminoglycoside against multidrug-resistant Pseudomonas aeruginosa in Japan. Jpn J Infect Dis 2012; 65: 84-7.
37. Xie ZD, Hershberger CD, Shankar S et al. Sigma factor-anti-sigma factor interaction in alginate synthesis: inhibition of AlgT by MucA. J Bacteriol 1996; 178: 4990-6.
38. Martin DW, Schurr MJ, Mudd MH et al. Mechanism of conversion to mucoidy in Pseudomonas aeruginosa infecting cystic fibrosis patients. Proc Natl Acad Sci USA 1993; 90: 8377-81.
39. Jones AK, Fulcher NB, Balzer GJ et al. Activation of the Pseudomonas aeruginosa AlgU regulon through mucA mutation inhibits cyclic AMP/Vfr signaling. J Bacteriol 2010; 192: 5709-17.
40. Khan W, Bernier SP, Kuchma SL et al. Aminoglycoside resistance of Pseudomonas aeruginosa biofilms modulated by extracellular polysaccharide. Int Microbiol 2010; 13: 207-12.
41. King P, Lomovskaya O, Griffith DC et al. In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. Antimicrob Agents Chemother 2010; 54: 143-8.
42. Ramsey BW, Dorkin HL, Eisenberg JD et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993; 328: 1740-6.
43. Ramsey BW, Pepe MS, Quan JM et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340: 23-30.
44. Konstan MW, Flume PA, Kappler M et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 2011; 10: 54-61.
45. Hancock RE. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative Gram-negative bacteria. Clin Infect Dis 1998; 27 Suppl 1: S93-9.